For the fiscal year ending February 2026, consolidated net sales were JPY 163.024 billion (an increase of 4.5% YoY), operating income was JPY 17.917 billion (a decrease of 5.2% YoY), and net income attributable to owners of parent was JPY 19.16 billion (a decrease of 11.9% YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4530","jir_company_name":"Hisamitsu Pharmaceutical Co., Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4530-20260413-01.pdf","jir_short_summary":"For the fiscal year ending February 2026, consolidated net sales were JPY 163.024 billion (an increase of 4.5% YoY), operating income was JPY 17.917 billion (a decrease of 5.2% YoY), and net income attributable to owners of parent was JPY 19.16 billion (a decrease of 11.9% YoY).","jir_summary":"### Overview of Performance\nFor the fiscal year ending February 2026, consolidated net sales amounted to JPY 163,024 million (up 4.5% YoY), operating income was JPY 17,917 million (down 5.2% YoY), ordinary income was JPY 23,952 million (down 0.2% YoY), and net income attributable to owners of parent was JPY 19,160 million (down 11.9% YoY). In the pharmaceutical business, promotional activities leveraging digital marketing focused on transdermal patches were advanced domestically and internationally. In the overseas over-the-counter pharmaceutical market, the Salonpas brand maintained its position as the No. 1 product by sales share and continued to be recognized as the world's No.1 brand.\n\n### Financial Position and Dividend Status\nAt the end of the fiscal year ending February 2026, total assets were JPY 367,162 million, net assets were JPY 294,694 million with an equity ratio of 79.4%. The number of shares outstanding was 75,164,895, with treasury shares reduced to 4,763,348. A year-end dividend of 60 yen (annual dividend of 60 yen) was paid, resulting in a dividend payout ratio of 22.3% and a return on equity-based dividend of 1.5%. Note that earnings forecast for the fiscal year ending February 2027 is not disclosed due to a planned delisting following a tender offer.","jir_financial_highlights":"Net Sales: 163,024 million JPY (4.5% increase YoY)\nOperating Income: 17,917 million JPY (5.2% decrease YoY)\nOrdinary Income: 23,952 million JPY (0.2% decrease YoY)\nNet Income Attributable to Owners of Parent: 19,160 million JPY (11.9% decrease YoY)\nEquity Ratio: 79.4% (Decrease YoY (80.6% \u2192 79.4%))\nShares Outstanding at Fiscal Year-End (Common Shares): 75,164,895 shares (Decrease YoY (85,164,895 shares \u2192 75,164,895 shares))\nAnnual Dividend (Year-End): 60 yen (Increase YoY (90 yen \u2192 60 yen) *Dividend forecast uncertain per note)","jir_category":"","jir_hashtags":"#HisamitsuPharmaceutical, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: 163,024 million JPY (4.5% increase YoY)\nOperating Income: 17,917 million JPY (5.2% decrease YoY)\nNet Income Attributable to Owners of Parent: 19,160 million JPY (11.9% decrease YoY)","jir_meta_title":"[Hisamitsu Pharmaceutical] FY2026 Financial Results | Sales JPY 163 Billion (YoY +4.5%)","jir_meta_description":"Hisamitsu Pharmaceutical Co., Inc. FY2026 Financial Summary. Consolidated net sales of JPY 163.024 billion (4.5% increase YoY), operating income of JPY 17.917 billion (5.2% decrease), and net income of JPY 19.16 billion (11.9% decrease). Year-end dividend of 60 yen.","jir_og_title":"[Hisamitsu Pharmaceutical] FY2026 Financial Results | Sales JPY 163 Billion (+4.5%)","jir_og_description":"Hisamitsu Pharmaceutical FY2026 financial summary. Net sales increased 4.5% YoY to JPY 163 billion, while operating income declined.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"FY2025\\\",\\\"FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[156006,163024],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"FY2025\\\",\\\"FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[18895,17917],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"FY2025\\\",\\\"FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[21758,19160],\\\"borderColor\\\":\\\"#3cba9f\\\",\\\"fill\\\":false}]}\"}, {\"jir_chart_id\": \"equity_ratio_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Equity Ratio Trend (%)\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"FY2025\\\",\\\"FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Equity Ratio\\\",\\\"data\\\":[80.6,79.4],\\\"borderColor\\\":\\\"#e8c3b9\\\",\\\"fill\\\":false}]}\"}, {\"jir_chart_id\": \"shares_outstanding_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Shares Outstanding at Fiscal Year-End Trend (Shares)\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"FY2025\\\",\\\"FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Shares Outstanding\\\",\\\"data\\\":[85164895,75164895],\\\"borderColor\\\":\\\"#c45850\\\",\\\"fill\\\":false}]}\"}]","ir_related_company":8125,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-40293","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n